文献速递神经肿瘤

脑肿瘤手术中神经导航的成功历程:从起源到应用与演进

Charting the success of neuronavigation in brain tumor surgery: from inception to adoption and evolution.
PubMed 文献 · J Neurooncol · 2024-07-24

该研究通过系统文献检索、NIH相对引用比与Altmetric评分影响分析及专利持有评估,追溯神经导航从1993年芬兰首篇发表到全球34国323项研究、逾19000例手术的应用历程,光学系统占58%、主要用于脑肿瘤手术(84%),美国研究引用影响高于国际研究。

要点

  • 首篇神经导航论文1993年来自芬兰,累计323项研究分布于34个国家。
  • 神经导航用于逾19000例手术,光学系统占58%,脑肿瘤手术占84%。
  • 美国研究RCR中位数1.71高于国际1.21(p<0.05),总体中位数1.37超过NIH资助研究1.0。

核心结论

  • 神经导航自三十年前起源以来已在全球被采用,并通过辅助技术整合不断演进以增强其有意义的使用。
  • 当前神经导航创新管线正在推进,学术与产业合作以促进其在脑肿瘤患者治疗中的进一步应用。

研究设计与样本

  • 三管齐下的方法:系统文献检索、使用NIH相对引用比(RCR)与Altmetric评分的影响分析、以及专利持有评估。
  • 数据按美国与国际背景二分。

主要发现

  • 首篇神经导航论文1993年来自芬兰,标志其起源。
  • 三十年间累计323项研究,发表趋势显著增加(r=0.74,p<0.05),分布于34个国家。
  • 神经导航以光学系统为主(58%),用于逾19000例病例,主要用于脑肿瘤手术(84%)。
  • 文献影响显示累计中位RCR评分超过NIH资助研究(1.37 vs 1.0),美国研究中位RCR显著高于国际(1.71 vs 1.21,p<0.05)。
  • 技术演进以辅助设备为特征,包括显微镜/外镜/内镜(21%)、MRI(17%)、超声(10%)和CT(7%)。

关键数值与推荐

  • 累计中位RCR评分1.37 vs NIH资助研究1.0。
  • 美国研究中位RCR 1.71 vs 国际1.21(p<0.05)。
  • 光学系统占58%,脑肿瘤手术占84%,显微镜/外镜/内镜占21%,MRI占17%,超声占10%,CT占7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neuronavigation, explored as an intra-operative adjunct for brain tumor surgery three decades ago, has become globally utilized with a promising upward trajectory. This study aims to chart its success from idea to adoption and evolution within the US and globally. METHODS: A three-pronged methodology included a systematic literature search, impact analysis using NIH relative citation ratio (RCR) and Altmetric scores, and assessment of patent holdings. Data was dichotomized for US and international contexts. RESULTS: The first neuronavigation publication stemmed from Finland in 1993, marking its inception. Over three decades, the cumulative number of 323 studies, along with the significantly increasing publication trend (r = 0.74, p < 0.05) and distribution across 34 countries, underscored its progressive and global adoption. Neuronavigation, mostly optical systems (58%), was utilized in over 19,000 cases, predominantly for brain tumor surgery (84%). Literature impact showed a robust cumulative median RCR score surpassing that for NIH-funded studies (1.37 vs. 1.0), with US studies having a significantly higher median RCR than international (1.71 vs. 1.21, p < 0.05). Technological evolution was characterized by adjuncts, including micro/exo/endoscope (21%), MRI (17%), ultrasound (10%), and CT (7%). Patent analysis demonstrated academic and industrial representation with an interdisciplinary convergence of medical and computational sciences. CONCLUSION: Since its inception thirty years ago, neuronavigation has been adopted worldwide, and it has evolved with adjunct technology integration to enhance its meaningful use. The current neuronavigation innovation pipeline is progressing, with academic and industry partnering to advance its further application in treating brain tumor patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Asfaw ZK, Young T, Brown C, et al. Charting the success of neuronavigation in brain tumor surgery: from inception to adoption and evolution. J Neurooncol. 2024. PMID: 39048723. doi:10.1007/s11060-024-04778-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。